DNA and Viral Vector Vaccine Experts are leading the charge in the development of innovative vaccine technologies that harness genetic material to trigger immune responses. DNA vaccines use plasmids—small, circular pieces of DNA—to deliver instructions to cells to produce specific proteins that stimulate immunity. Meanwhile, viral vector vaccines employ modified viruses to carry genetic material into cells, prompting them to create antigens that activate the immune system. These scientists focus on refining and optimizing these platforms, ensuring their safety, efficacy, and scalability for widespread use. Their work is crucial in addressing complex diseases and has been instrumental in accelerating vaccine development timelines, offering a promising alternative to traditional vaccine methods.
These experts also work on enhancing the delivery systems of DNA and viral vector vaccines to improve stability, reduce production costs, and increase global accessibility. Through rigorous preclinical and clinical trials, they test the safety and effectiveness of these vaccines, refining their formulations based on data. DNA and viral vector vaccines have shown promise in combating diseases such as COVID-19, Ebola, and Zika , and their potential to target a wide array of conditions, including cancer, continues to expand. DNA and viral vector vaccine experts are reshaping the future of immunization, providing faster, adaptable solutions for global health challenges. Their groundbreaking work is crucial in advancing vaccine science and offering hope for a future where more diseases can be prevented with innovative vaccines.
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : Capillary electrophoresis for adjuvanted multivalent recombinant vaccine purity determination
Ashley Prout, Merck, United States
Title : Hypersensitivity and anti-SARS-COV-2 vaccination: A retrospective study of the year 2021 at the University Hospital Center of Tours (France)
Faure Quentin, The Savoie Metropolitan Hospital Center, France
Title : THE HPV vaccination program in Colombia. From a beautiful dream to a nightmare, but hopefully with a bright dawn.
Carlos Castro, Colombian League against cancer, Colombia